Is pembrolizumab as safe and efficient as neoadjuvant treatment in localized dMMR/MSI esophagogastric cancers? Results from the IMHOTEP phase II study
Open Access
Abstract
No abstract availableKeywords
Funding Information
- Direction de l’hospitalisation et de l’offre de Soins
- Institut National Du Cancer (PHRC-K 2019 Inca-DGOS_14333)
- Institut National Du Cancer (PRT-K 2020-15324)
- Institut National Du Cancer (INCa-DGOS-INSERM-ITMO cancer_18003)
- Ministère des Solidarités et de la Santé
- Merck Sharp and Dohme France
This publication has 20 references indexed in Scilit:
- The Duration of Immunotherapy for Mismatch Repair–Deficient CancersNew England Journal of Medicine, 2025
- Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONOAnnals of Oncology, 2024
- Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 studyAnnals of Oncology, 2024
- 1448P IMHOTEP phase II trial of neoadjuvant pembrolizumab in dMMR/MSI localized cancers: Results of the digestive non-colorectal cancer cohortsAnnals of Oncology, 2024
- Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair–Deficient Colon CancerNew England Journal of Medicine, 2024
- Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 studyThe Lancet Oncology, 2023
- Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trialDigestive and Liver Disease, 2022
- Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal CancerNew England Journal of Medicine, 2020
- Mismatch Repair Deficiency, Microsatellite Instability, and SurvivalJAMA Oncology, 2017
- Comprehensive molecular characterization of gastric adenocarcinomaNature, 2014